Telomir Pharmaceuticals, Inc. (TELO) stock
TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.42−0.06 (-12.04%)
Close on Nov 17, 2026Market cap $29.10MP/E –Yield –
Telomir Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | $2.19M | – |
| Q1 FY2024 | Mar 31, 2024 | $1.92M | – |
See a number that looks wrong?